Vogenx

Update in progress

VOGX (NasdaqCM)

Vogenx, Inc. is a clinical-stage drug development company focused on metabolic disorders, including post-bariatric hypoglycemia (PBH) and gastroparesis. Its product candidates include Mizagliflozin and VGX-2857, along with VGX-001, a human monoclonal antibody for type 1 diabetes. The company serves healthcare providers, physicians, and third-party payors in the United States. Founded in 2021, it is based in Raleigh, North Carolina.